Announced details
Myeloid malignancies, including relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS)
ORR of 11.8% (4/34 patients), CRi in 3 patients with AML, mCR in 1 patient with MDS, and a reduction of 50% or more in bone marrow blasts in 5 of 14 patients with splicing mutations
34 evaluable patients and 42 patients enrolled in the trial (23 with AML, 16 with MDS and 3 with CMML)
A forum for presenting data from clinical trials conducted by the Company. Capital, personnel and business relationships are not disclosed.
A professional association in the field of hematology. Other information, including its location, representative and business activities, is not disclosed.
NCT05732103 (clinical trial registration number); expiration date not disclosed
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
European Hematology Association (EHA) abstract No. EHA-3974; NCT05732103; Yokoyama H et al., Blood Advances 2026; 10(1): 262-272; Sato J et al., Clin Cancer Res. 2026; doi: 10.1158/1078-0432.CCR-25-4896
| Item | Details |
|---|---|
| Names of Products / Services Covered | rogocekib（CTX-712） |
| Counterparty | European Hematology Association (EHA) |
| Counterparty overview | A professional association in the field of hematology. Other information, including its location, representative and business activities, is not disclosed. |
| Relationship with the Company | A forum for presenting data from clinical trials conducted by the Company. Capital, personnel and business relationships are not disclosed. |
| Launch date | 13 June 2026 (described as a poster presentation; whether it is scheduled or has already taken place is not specified) |
| Applicable area | Myeloid malignancies, including relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) |
| Registration number and expiry date | NCT05732103 (clinical trial registration number); expiration date not disclosed |
| Quantitative Effects | ORR of 11.8% (4/34 patients), CRi in 3 patients with AML, mCR in 1 patient with MDS, and a reduction of 50% or more in bone marrow blasts in 5 of 14 patients with splicing mutations |
| Usage history | 34 evaluable patients and 42 patients enrolled in the trial (23 with AML, 16 with MDS and 3 with CMML) |
| Source | European Hematology Association (EHA) abstract No. EHA-3974; NCT05732103; Yokoyama H et al., Blood Advances 2026; 10(1): 262-272; Sato J et al., Clin Cancer Res. 2026; doi: 10.1158/1078-0432.CCR-25-4896 |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because rogocekib demonstrated antitumor activity as monotherapy and manageable safety even in a patient population of older adults with multiple prior lines of treatment and limited treatment options.